Peptic ulcer disease before and after introduction of new drugs-a comparison from surgeon's point of view
Jerzy Janik, Piotr ChwirotMed Sci Monit 2000; 6(2): EP365-368 :: ID: 508544
Abstract
During the last twenty years we have witnessed a revolutionary change in treatment and diagnosis of peptic ulcer disease (PUD). It was introduction of flexible fiberoptic instruments and new drugs: H-2 blockers, proton pump inhibitors (PPI) and treatment against Helicobacter pylori which affected most significantly the course of this illness. Although indications for surgical intervention have not been changed, practice of surgery in this regard has changed a lot. In this report two periods of time were analyzed and compared: years 1977-81 and 1992-96. Operation reports from the above defined periods were reviewed and all surgeries performed for PUD and its complications have been noted along with data regarding patients and indications for surgery as reported by operating surgeons. There were 360 surgeries for PUD performed in the 1977-1981 period, and 246 in the years 1992-1996. Patients were divided into groups depending on indications for surgery. A significant reduction in the general number of operations performed was noted. The percentage of women operated upon increased. The mean age of patients in all indication groups was higher in the latter period. Patients operated for bleeding tended to be older than those in perforation and intractable disease groups. This was true in both periods of time. The number and percentage of patients operated for perforation increased. The natural course of PUD is changing; intractable disease as an indication for surgery is disappearing, the number of pyloric obstruction patients is diminishing, the incidence of bleeding and perforation remains constant. The mean age of patients and percentage of women is increasing.
key words: peptic ulcer disease • complication rate • indication for surgery
Keywords: indication for surgery, complication rate, peptic ulcer disease
Editorial
01 March 2025 : Editorial
Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical TrialsDOI: 10.12659/MSM.948672
Med Sci Monit 2025; 31:e948672
In Press
Clinical Research
Comparative Analysis of Laser Therapies for Striae Distensae: Fractional CO₂ vs Combined Q-Switch Nd:YAGMed Sci Monit In Press; DOI: 10.12659/MSM.947464
Database Analysis
Utility of Central Venous Oxygen Saturation Gradient in Predicting Mortality in Dialysis with Catheter AccessMed Sci Monit In Press; DOI: 10.12659/MSM.947298
Clinical Research
Intraoperative Renal Near-Infrared Spectroscopy Monitoring as a Predictor of Renal Outcomes in Cardiac SurgeryMed Sci Monit In Press; DOI: 10.12659/MSM.947462
Clinical Research
Impact of Cholecalciferol Supplementation on Radiotherapy Outcomes in Advanced Cervical CancerMed Sci Monit In Press; DOI: 10.12659/MSM.945964
Most Viewed Current Articles
17 Jan 2024 : Review article 7,110,480
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,343
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 27,671
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 21,887
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912